XML 85 R45.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment and Geographic Data (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
Segment Results | 2024 |  | 2023 |  | 2022
MedSurg and Neurotechnology | $ | 13,518 |  |  | $ | 12,163 |  |  | $ | 10,893 |
Orthopaedics | $ | 9,077 |  |  | 8,335 |  |  | 7,556 |
Net sales | $ | 22,595 |  |  | $ | 20,498 |  |  | $ | 18,449 |
MedSurg and Neurotechnology | $ | 5,320 |  |  | $ | 4,876 |  |  | $ | 4,637 |
Orthopaedics | $ | 2,400 |  |  | 2,254 |  |  | 1,920 |
Cost of sales | $ | 7,720 |  |  | $ | 7,130 |  |  | $ | 6,557 |
MedSurg and Neurotechnology | $ | 784 |  |  | $ | 702 |  |  | $ | 682 |
Orthopaedics | $ | 540 |  |  | 508 |  |  | 477 |
Segment research, development and engineering expenses | $ | 1,324 |  |  | $ | 1,210 |  |  | $ | 1,159 |
MedSurg and Neurotechnology | $ | 3,203 |  |  | $ | 2,934 |  |  | $ | 2,564 |
Orthopaedics | $ | 3,111 |  |  | 2,922 |  |  | 2,608 |
Segment selling, general and administrative expenses | $ | 6,314 |  |  | $ | 5,856 |  |  | $ | 5,172 |
MedSurg and Neurotechnology | $ | 208 |  |  | $ | 181 |  |  | $ | 178 |
Orthopaedics | 433 |  |  | 386 |  |  | 350 |
Segment depreciation and amortization | $ | 641 |  |  | $ | 567 |  |  | $ | 528 |
Corporate and Other | 162 |  |  | 139 |  |  | 123 |
Amortization of intangible assets | 623 |  |  | 635 |  |  | 627 |
Total depreciation and amortization | $ | 1,426 |  |  | $ | 1,341 |  |  | $ | 1,278 |
MedSurg and Neurotechnology | $ | 4,004 |  |  | $ | 3,470 |  |  | $ | 2,831 |
Orthopaedics | 2,591 |  |  | 2,265 |  |  | 2,202 |
Segment operating income | $ | 6,595 |  |  | $ | 5,735 |  |  | $ | 5,033 |
Items not allocated to segments: |  |  |  |  |
Corporate and Other | $ | (880) |  |  | $ | (780) |  |  | $ | (649) |
Inventory stepped up to fair value | (46) |  |  | — |  |  | — |
Acquisition and integration-related charges | (108) |  |  | (20) |  |  | (138) |
Amortization of intangible assets | (623) |  |  | (635) |  |  | (627) |
Structural optimization and other special charges | (138) |  |  | (170) |  |  | (295) |
Goodwill and other impairments | (977) |  |  | (36) |  |  | (270) |
Medical device regulation | (58) |  |  | (96) |  |  | (140) |
Recall-related matters | (40) |  |  | (18) |  |  | 15 |
Regulatory and legal matters | (36) |  |  | (92) |  |  | (76) |
Consolidated operating income | $ | 3,689 |  |  | $ | 3,888 |  |  | $ | 2,841 |
Sales and Other Financial Information by Business Segment |
Segment Assets and Capital Spending
Assets: | 2024 |  | 2023 |  |
MedSurg and Neurotechnology | $ | 23,115 |  |  | $ | 20,804 |  |  |
Orthopaedics | 18,507 |  |  | 18,023 |  |  |
Total segment assets | $ | 41,622 |  |  | $ | 38,827 |  |  |
Corporate and Other | 1,349 |  |  | 1,085 |  |  |
Total assets | $ | 42,971 |  |  | $ | 39,912 |  |  |
Purchases of property, plant and equipment: | 2024 |  | 2023 |  | 2022
Orthopaedics | $ | 230 |  |  | $ | 179 |  |  | $ | 173 |
MedSurg and Neurotechnology | 276 |  |  | 183 |  |  | 175 |
Total segment purchases of property, plant and equipment | $ | 506 |  |  | $ | 362 |  |  | $ | 348 |
Corporate and Other | 249 |  |  | 213 |  |  | 240 |
Total purchases of property, plant and equipment | $ | 755 |  |  | $ | 575 |  |  | $ | 588 |
Geographic Information on Net Sales and Long-Lived Assets |
Geographic Information
| Net Sales |  | Net Property, Plant and Equipment
| 2024 |  | 2023 |  | 2022 |  | 2024 |  | 2023
United States | $ | 16,943 |  |  | $ | 15,257 |  |  | $ | 13,638 |  |  | $ | 1,997 |  |  | $ | 1,874 |
Europe, Middle East, Africa | 2,897 |  |  | 2,618 |  |  | 2,348 |  |  | 1,260 |  |  | 1,151 |
Asia Pacific | 2,020 |  |  | 1,946 |  |  | 1,885 |  |  | 75 |  |  | 77 |
Other countries | 735 |  |  | 677 |  |  | 578 |  |  | 116 |  |  | 113 |
Total | $ | 22,595 |  |  | $ | 20,498 |  |  | $ | 18,449 |  |  | $ | 3,448 |  |  | $ | 3,215 |

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration